

8 January 2010

Lifeline Scientific, Inc.

(“Lifeline” or the “Company”)

Exercise of options

Lifeline Scientific, the medical technology company focused on commercialising its advanced organ preservation and transport systems, designed to address the global challenge of human donor organ shortages, announces that on 5 January 2010 Lisa Kieres, Chief Financial Officer, member of the senior management team, exercised 8,660 of her vested options granted on 20 October 2009.

Application has been made for the admission of the 8,660 shares to trading on the AIM market. Admission is expected to occur on 14 January 2010.

Enquiries:

Lifeline Scientific, Inc.

+1 847 824 2420

David Kravitz, CEO

Seymour Pierce

+44 (0)20 7107 8000

Mark Percy / Huaizheng Peng / Sarah Jacobs

Financial Dynamics

+44 (0)20 7831 3113

Ben Brewerton / John Dineen